KRAS G12C Emerges as New Potential Target in Non-Small Cell Lung Cancer

Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer (NSCLC).

The class of agents Garon finds exciting in the field of NSCLC is the KRAS G12C inhibitors. These agents have generating a lot of enthusiasm as the KRAS mutation is a very trackable target, and KRAS also appears to be very prevalent in NSCLC. Garon says KRAS is similar to EGFR mutations in terms of prevalence in NSCLC.

There is new data emerging now and clinical trials evaluating this target in NSCLC, Garon adds. It will be exciting to see how these therapies evolve as treatment of patients with NSCLC who may harbor a KRAS mutation.

<<View data for a novel KRAS G12C inhibitor as treatment of multiple solid tumors